CYCN Share Price Performance
US$2.52
-0.08 (-3.08%)
Price US$2.52
Share PriceUS$2.52
Cyclerion Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
CYCN Community Narratives
There are no narratives available yet.
Recent CYCN News & Updates
Cyclerion Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.61
- Gross Margin
- 102.62%
- Net Profit Margin
- -89.51%
- Debt/Equity Ratio
- 0%
Cyclerion Therapeutics, Inc. Competitors
Snowflake Analysis
About CYCN
- Founded
- 2018
- Employees
- 1
- CEO
- WebsiteView website
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.4%
- 3 Months: 7.8%
- 1 Year: 17.8%
- Year to Date: 14.7%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 3.7% in that time. As for the longer term, the market has risen 18% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›